Who
Duncan McKechnie
EVP, Chief Commercial Officer
Company insider
Files Form 4 as: EVP, Chief Commercial Officer, Vertex Pharmaceuticals.
In numbers
- Trades disclosed
- 24
- Buys
- 0
- Sells
- 4
- Bought
- $0
- Sold
- $11.3M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 22 Jan 2026
- Last trade
- 2 Jul 2026
- Last filed
- 7 Jul 2026
Companies traded
Activity over time
1 Feb – 1 Oct
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 2 Jul 2026filed 7 Jul 2026 | VRTX Vertex PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $800K1,541 at $519.00 | filing |
| 2 Jul 2026filed 7 Jul 2026 | VRTX Vertex PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $800K1,541 at $519.00 | filing |
| 11 Mar 2026filed 13 Mar 2026 | VRTX Vertex PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $1.3M2,633 at $498.42 | filing |
| 11 Mar 2026filed 13 Mar 2026 | VRTX Vertex PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $1.3M2,633 at $498.42 | filing |
| 4 Mar 2026filed 6 Mar 2026 | VRTX Vertex PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $1.2M2,437 at $475.30 | filing |
| 4 Mar 2026filed 6 Mar 2026 | VRTX Vertex PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $1.2M2,437 at $475.30 | filing |
| 25 Feb 2026filed 26 Feb 2026 | VRTX Vertex PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $1.2M2,500 at $486.35 | filing |
| 25 Feb 2026filed 26 Feb 2026 | VRTX Vertex PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $1.2M2,410 at $489.00 | filing |
| 25 Feb 2026filed 26 Feb 2026 | VRTX Vertex PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $1.2M2,500 at $486.35 | filing |
| 25 Feb 2026filed 26 Feb 2026 | VRTX Vertex PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $1.2M2,410 at $489.00 | filing |
| 24 Feb 2026filed 26 Feb 2026 | VRTX Vertex PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $424K873 at $485.11 | filing |
| 24 Feb 2026filed 26 Feb 2026 | VRTX Vertex PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $424K873 at $485.11 | filing |
| 17 Feb 2026filed 19 Feb 2026 | VRTX Vertex PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —4,962 at $0.00 | filing |
| 17 Feb 2026filed 19 Feb 2026 | VRTX Vertex PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $555K1,148 at $483.75 | filing |
| 17 Feb 2026filed 19 Feb 2026 | VRTX Vertex PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —4,962 at $0.00 | filing |
| 17 Feb 2026filed 19 Feb 2026 | VRTX Vertex PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $555K1,148 at $483.75 | filing |
| 13 Feb 2026filed 18 Feb 2026 | VRTX Vertex PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $1.1M2,283 at $487.76 | filing |
| 13 Feb 2026filed 18 Feb 2026 | VRTX Vertex PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $1.1M2,283 at $487.76 | filing |
| 10 Feb 2026filed 12 Feb 2026 | VRTX Vertex PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $528K1,127 at $468.41 | filing |
| 10 Feb 2026filed 12 Feb 2026 | VRTX Vertex PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $528K1,127 at $468.41 | filing |
News
Head to Head Analysis: Caribou Biosciences (NASDAQ:CRBU) & Vertex Pharmaceuticals (NASDAQ:VRTX)VRTX · tickerreport.com · 14 Oct 2026Vertex Pharmaceuticals Incorporated: Vertex to Present New Data on ALYFTREK at the North American Cystic Fibrosis ConferenceVRTX · finanznachrichten.de · 9 Oct 2026
0 headlines in the last 90 days name Duncan McKechnie; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.